Figure 7
Figure 7. TCL171-78 peptide-specific T cells are increased in lymphoma patients. PBMCs from HLA-A2+ ND (n = 8) or lymphoma patients (CLL, n = 2; MCL, n = 5; FL, n = 4; DLBCL, n = 2; and SMZL, n = 2) were stimulated in vitro twice with TCL165-79 peptide and stained with TCL171-78 tetramer or HIV Gag77-85 tetramer. Representative data of the tetramer staining (A) and results from all samples analyzed (B) are shown. P value on the top of graph represents comparison between normal donors and all lymphoma patient samples. P values to the right represent comparison between normal donors and patients from each lymphoma subtype. All P values were calculated by 2-tailed Student t test.

TCL171-78 peptide-specific T cells are increased in lymphoma patients. PBMCs from HLA-A2+ ND (n = 8) or lymphoma patients (CLL, n = 2; MCL, n = 5; FL, n = 4; DLBCL, n = 2; and SMZL, n = 2) were stimulated in vitro twice with TCL165-79 peptide and stained with TCL171-78 tetramer or HIV Gag77-85 tetramer. Representative data of the tetramer staining (A) and results from all samples analyzed (B) are shown. P value on the top of graph represents comparison between normal donors and all lymphoma patient samples. P values to the right represent comparison between normal donors and patients from each lymphoma subtype. All P values were calculated by 2-tailed Student t test.

Close Modal

or Create an Account

Close Modal
Close Modal